Autologous regenerative medicine company Aspen Neuroscience announced on Thursday that it has completed dosing of the first cohort of patients in its ASPIRO study.

Surgical safety data from this cohort has been accepted for late breaking presentations at the MDS International Congress of Parkinson's Disease and Movement Disorders, taking place in Philadelphia from 27 September to 1 October.

The Autologous-derived Study of a Parkinson's Investigational Regenerative therapy in an Open-label trial (ASPIRO) is a Phase 1/2a clinical trial to assess the safety, tolerability and potential efficacy of ANPD001 in patients with moderate to severe Parkinson's disease (PD). The primary endpoint of the study is safety and tolerability of ANPD001.